阿莫西林-克拉维酸序贯治疗社区获得性急性下呼吸道感染的临床疗效

Clinical analysis of amoxicillin-clavulanic acid consecutive therapy in treating acute community-acquired low respiratory tract infections

目的评价阿莫西林-克拉维酸序贯治疗社区获得性急性下呼吸道感染的临床疗效和安全性。方法68例社区获得性急性下呼吸道感染患者被随机分成2组,各34例。A组予阿莫西林-克拉维酸注射液1.2 g,iv gtt,bid×10 d;B组先用阿莫西林-克拉维酸注射液1.2 g,iv gtt,bid×3 d后,改为阿莫西林-克拉维酸0.5 g,po,bid×7 d,总疗程10 d。结果A组与B组的治疗有效率分别为85%和82%,细菌清除率分别为84%和83%,P均>0.05,2组的不良反应率相似。结论阿莫西林-克拉维酸序贯治疗社区获得性急性下呼吸道感染的临床疗效确切,安全。

AIM To evaluate the efficacy and safety of amoxicillin-clavulanic acid consecutive therapy in treating acute community-acquired low respiratory tract infections. METHODS Sixty-eight patients with acute community-acquired low respiratory tract infection were randomly divided into 2 groups. Thirty-four patients of group A were treated with amoxycillin sodium and potassium clavulanate 1.2 g,iv gtt, bid for 10 d. Thirty-four patients of group B were received consecutive therapy of amoxicillin-clavulanic acid 1.2 g, iv gtt, bid for 3 d then 0.5 g, po, bid for 7 d. RESULTS The clinical effective rates of group A and group B were 85% and 82%,respectively. Bacterial clearance rates of group A and group B were 84% and 83%,respectively. There was no significant difference (P>0.05) in clinical effective rates and bacterial clearance rates between 2 groups. But the cost-effectiveness of group B was superior to group A(P<0.05). The occurrence rates of the adverse drug reactions between 2 groups were similar. CONCLUSION Amoxicillin-clavulanic acid consecutive therapy in treating acute community-acquired low respiratory tract infections is effective and safe.